Overcoming bioethical, legal, and hereditary barriers to mitochondrial replacement therapy in the USA.
Level 5 - mechanism / opinion, no new human data
Narrative review, legal commentary, and ethical analysis with no new empirical human data.
PubMed 30554395 · doi:10.1007/s10815-018-1370-7
What was done
This paper provides a narrative review and legal-ethical policy analysis examining the US regulatory restrictions on mitochondrial replacement therapy (MRT). The authors review ethical arguments, genetic heredity concepts, economic impacts of mitochondrial disease, reproductive rights jurisprudence, and federal statutory definitions concerning heritable genetic modifications.
What was found
The abstract reports no empirical data, trial results, or numerical statistics. The authors argue conceptually that MRT replaces mutated organelles rather than altering nuclear genomes, meaning it falls outside legislative prohibitions against heritable genetic engineering, and assert that legal and educational reframing could prompt regulatory reconsideration by the FDA.
Why it matters
It outlines the primary legal, bioethical, and definitional arguments used by proponents seeking to lift clinical prohibitions on mitochondrial replacement therapy in the United States.
Limits
This is a theoretical and policy commentary rather than a clinical trial or systematic review. It provides no primary clinical data on procedural safety, long-term health outcomes of MRT offspring, or empirical cost-effectiveness metrics.
Cited by
- supports Mitochondrial replacement therapy (three-parent IVF) is not legally permitted in the United States.